Lord, Abbett & Co. LLC Glaukos Corp Transaction History

Lord, Abbett & Co. LLC

$31.4 Billion
Q3 2024

A detailed history of Lord, Abbett & Co. LLC transactions in Glaukos Corp stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 1,528,515 shares of GKOS stock, worth $220 Million. This represents 0.63% of its overall portfolio holdings.

Number of Shares

1,528,515

Previous 1,528,515 -0.0%

Holding current value

$220 Million

Previous $199 Million -0.0%

% of portfolio

0.63%

Previous 0.65%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$113.62 - $135.39 $17.2 Million - $20.5 Million	151,082 Added 10.97%	1,528,515 $199 Million
Q2 2024 Oct 07, 2024	SELL	$89.48 - $118.35 $12.2 Million - $16.2 Million	-136,462 Reduced 9.01%	1,377,433 $163 Million
Q2 2024 Aug 14, 2024	SELL	$89.48 - $118.35 $12.2 Million - $16.2 Million	-136,462 Reduced 9.01%	1,377,433 $163 Million
Q1 2024 Oct 07, 2024	BUY	$76.4 - $96.33 $78.8 Million - $99.3 Million	1,031,074 Added 213.55%	1,513,895 $143 Million
Q1 2024 May 09, 2024	BUY	$76.4 - $96.33 $78.8 Million - $99.3 Million	1,031,074 Added 213.55%	1,513,895 $143 Million
Q4 2023 Oct 07, 2024	SELL	$59.53 - $85.11 $15.4 Million - $22.1 Million	-259,126 Reduced 34.93%	482,821 $38.4 Million
Q4 2023 Feb 12, 2024	SELL	$59.53 - $85.11 $15.4 Million - $22.1 Million	-259,126 Reduced 34.93%	482,821 $38.4 Million
Q3 2023 Oct 07, 2024	SELL	$69.23 - $79.09 $886,697 - $1.01 Million	-12,808 Reduced 1.7%	741,947 $55.8 Million
Q3 2023 Nov 13, 2023	SELL	$69.23 - $79.09 $886,697 - $1.01 Million	-12,808 Reduced 1.7%	741,947 $55.8 Million
Q2 2023 Oct 07, 2024	BUY	$45.44 - $71.21 $18.5 Million - $29 Million	407,584 Added 117.4%	754,755 $53.7 Million
Q2 2023 Aug 14, 2023	BUY	$45.44 - $71.21 $18.5 Million - $29 Million	407,584 Added 117.4%	754,755 $53.7 Million
Q1 2023 Oct 07, 2024	SELL	$43.88 - $52.48 $25.1 Million - $30.1 Million	-573,034 Reduced 62.27%	347,171 $17.4 Million
Q1 2023 May 12, 2023	SELL	$43.88 - $52.48 $25.1 Million - $30.1 Million	-573,034 Reduced 62.27%	347,171 $17.4 Million
Q4 2022 Oct 07, 2024	SELL	$40.82 - $57.75 $18.7 Million - $26.4 Million	-457,228 Reduced 33.19%	920,205 $40.2 Million
Q4 2022 Feb 10, 2023	SELL	$40.82 - $57.75 $9.25 Million - $13.1 Million	-226,610 Reduced 19.76%	920,205 $40.2 Million
Q3 2022 Nov 14, 2022	BUY	$46.84 - $58.49 $53.7 Million - $67.1 Million	1,146,815 New	1,146,815 $61.1 Million
Q1 2020 May 14, 2020	SELL	$25.53 - $70.14 $7.8 Million - $21.4 Million	-305,549 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$54.18 - $65.64 $31.2 Million - $37.8 Million	-575,664 Reduced 65.33%	305,549 $16.6 Million
Q3 2019 Nov 14, 2019	SELL	$58.58 - $83.91 $27.6 Million - $39.5 Million	-470,911 Reduced 34.83%	881,213 $55.1 Million
Q2 2019 Aug 14, 2019	SELL	$63.59 - $78.71 $33 Million - $40.8 Million	-518,191 Reduced 27.71%	1,352,124 $102 Million
Q1 2019 May 15, 2019	SELL	$50.75 - $80.54 $12 Million - $19 Million	-235,765 Reduced 11.19%	1,870,315 $147 Million
Q4 2018 Feb 14, 2019	BUY	$52.18 - $67.93 $12.4 Million - $16.2 Million	238,254 Added 12.76%	2,106,080 $118 Million
Q3 2018 Nov 14, 2018	BUY	$38.13 - $68.37 $30.3 Million - $54.3 Million	793,623 Added 73.88%	1,867,826 $121 Million
Q2 2018 Aug 14, 2018	BUY	$27.62 - $44.51 $25.5 Million - $41.1 Million	922,387 Added 607.57%	1,074,203 $43.7 Million
Q1 2018 May 15, 2018	BUY	$26.05 - $34.5 $1.72 Million - $2.28 Million	66,153 Added 77.22%	151,816 $4.68 Million
Q4 2017 Feb 14, 2018	SELL	$24.5 - $36.01 $7.43 Million - $10.9 Million	-303,340 Reduced 77.98%	85,663 $2.2 Million
Q3 2017 Nov 14, 2017	SELL	$31.26 - $42.03 $13.2 Million - $17.7 Million	-422,030 Reduced 52.04%	389,003 $12.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	811,033	811,033 $33.6 Million

Others Institutions Holding GKOS

# of Institutions

341

Shares Held

46.8M

Call Options Held

132K

Put Options Held

188K

View Full List

About GLAUKOS Corp

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $6.84B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

More about GKOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Account

Lord, Abbett & Co. LLC Glaukos Corp Transaction History